Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation
- 1 July 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 6 (4), 740-747
- https://doi.org/10.1161/circheartfailure.113.000212
Abstract
Background—In Rivaroxaban Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), rivaroxaban was noninferior to warfarin for the prevention of stroke and systemic embolic events and significantly reduced intracranial bleeding in patients with nonvalvular atrial fibrillation. We explore the safety and efficacy of rivaroxaban in patients with heart failure (HF). Methods and Results—A total of 9033 (63.7%) patients had HF. The primary efficacy analysis was rates of stroke or systemic embolism (per 100 patient-years) by intention to treat. The safety outcomes were major or nonmajor clinically relevant bleeding and hemorrhagic stroke during treatment. Patients with HF were younger (72 versus 74 years), more likely to have persistent atrial fibrillation (83.0% versus 77.6%), and had higher mean CHADS2 scores (3.7 versus 3.1). The efficacy of rivaroxaban compared with warfarin was similar in patients with HF...This publication has 42 references indexed in Scilit:
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort studyBMJ, 2011
- Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral AnticoagulationCirculation: Cardiovascular Quality and Outcomes, 2011
- Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)Journal of Thrombosis and Haemostasis, 2010
- Twelve‐month outcomes and predictors of very stable INR control in prevalent warfarin usersJournal of Thrombosis and Haemostasis, 2010
- Outcomes and predictors of very stable INR control during chronic anticoagulation therapyBlood, 2009
- Heart Failure Is a Risk Factor for Orthopedic FractureCirculation, 2008
- ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive SummaryCirculation, 2006
- Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) StudyAmerican Heart Journal, 2005
- Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)American Heart Journal, 2005